Qiagen NV (QGEN) PT Raised to $43 at BofA/Merrill Lynch
Tweet
Share
E-mailGet Alerts QGEN Hot Sheet
Price: $44.20 +1.87%
Rating Summary:
14 Buy, 17 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 11 | New: 32
Rating Summary:
14 Buy, 17 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 11 | New: 32
Join SI Premium – FREE
BofA/Merrill Lynch analyst Derik de Bruin raised the price target on Qiagen NV (NYSE: QGEN) to $43.00 (from $40.00) while maintaining a Neutral rating following analyst day.
- Updated mid-term guide mostly in-line with our expectations
- Mid-term guide of 8-9% CER sales; ~10% EPS CAGR
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sprinklr Inc (CXM) PT Raised to $7.50 at Cantor Fitzgerald
- Wedbush Downgrades Tscan Therapeutics Inc (TCRX) to Neutral
- MiniMed Group (MMED) PT Raised to $27 at StoneX on Conservative Revenue Guide
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Derik de Bruin, BofA/Merrill LynchSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
